Related Experiment Video

Updated: May 6, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

806

Type D personality predicts poor medication adherence in patients with heart failure in the USA

Jia-Rong Wu1, Debra K Moser

  • 1School of Nursing, University of North Carolina at Chapel Hill, 435 Carrington Hall, CB# 7460, Chapel Hill, NC, 27599-7460, USA, jiarongw@email.unc.edu.

International Journal of Behavioral Medicine
|November 8, 2013
PubMed

Insights

Type D personality was linked to poorer medication adherence in heart failure patients. Negative affectivity, a component of Type D personality, was specifically associated with medication adherence challenges.

Area of Science:

  • Cardiology
  • Psychology
  • Behavioral Science

Background:

  • Type D (distressed) personality is linked to adverse health outcomes and medication nonadherence.
  • Previous research shows Type D personality is associated with poor medication adherence in coronary artery disease patients.
  • The relationship between Type D personality and medication adherence in heart failure (HF) patients is not well understood.

Purpose of the Study:

  • To investigate the association between Type D personality and medication adherence in patients diagnosed with heart failure.
  • To determine if personality traits influence medication adherence in a heart failure population.

Main Methods:

  • A sub-analysis of baseline data from a randomized controlled trial involving 84 US-based heart failure patients.
  • Assessment of Type D personality using the Type D Personality Scale (DS14).
  • Measurement of medication adherence using objective (Medication Event Monitoring System) and self-reported (Morisky Medication Adherence Scale) methods.

Main Results:

  • Patients with Type D personality demonstrated a higher likelihood of poor medication adherence.
  • Type D personality, when treated as a categorical variable, showed a significant association with medication adherence, even after adjusting for covariates.
  • Negative affectivity, a facet of Type D personality, was found to be significantly associated with medication adherence.

Conclusions:

  • Type D personality as a dimensional construct may not fully capture the personality components linked to poor health outcomes.
  • Negative affectivity is a key component of Type D personality associated with medication adherence in heart failure patients.
  • Interventions to improve medication adherence should consider patients with high negative affectivity, who are at increased risk for nonadherence and adverse health outcomes.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
450
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
400
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641